Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 11/20 | 0.44 |
| ▸ | LY96 | Q9Y6Y9 | 6/20 | 0.43 |
| ▸ | PRKCA | P17252 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10447319 | 1.00 | TLR4 (0.44) | TLR4LY96PRKCA | |
| SCHEMBL3901023 | 0.96 | TLR4 (0.42) | TLR4LY96PRKCA | |
| SCHEMBL597451 | 0.95 | TLR4 (0.42) | TLR4LY96PRKCA | |
| SCHEMBL30277900 | 0.95 | TLR4 (0.42) | TLR4LY96PRKCA | |
| SCHEMBL19138246 | 0.95 | TLR4 (0.46) | TLR4LY96PRKCA | |
| SCHEMBL30277904 | 0.95 | TLR4 (0.42) | TLR4LY96PRKCA | |
| SCHEMBL21531505 | 0.95 | TLR4 (0.42) | TLR4LY96PRKCA | |
| SCHEMBL29431102 | 0.93 | TK2 (0.40) | TLR4LY96 | |
| SCHEMBL28381771 | 0.93 | TK2 (0.40) | TLR4LY96 | |
| SCHEMBL29362128 | 0.93 | TK2 (0.40) | TLR4LY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3193834-A1 | PRE-SPRAY EMULSIONS AND POWDERS CONTAINING NON-POLAR COMPOUNDS | VIRUN, INC. (US) | 2017-07-26 | — | — | EP | claimed |
| US-20160193146-A1 | COMPOSITIONS CONTAINING NON-POLAR COMPOUNDS | VIRUN, INC. | 2016-07-07 | — | — | US | claimed |
| EP-2563164-B1 | NANOEMULSION INCLUDING SUCROSE FATTY ACID ESTER | VIRUN INC (US) | 2016-06-29 | — | — | EP | claimed |
| WO-2016044813-A9 | PRE-SPRAY EMULSIONS AND POWDERS CONTAINING NON-POLAR COMPOUNDS | VIRUN, INC. (US) | 2016-05-26 | — | — | WO | claimed |
| US-9320295-B2 | Compositions containing non-polar compounds | VIRUN, INC. (US) | 2016-04-26 | — | — | US | claimed |
| WO-2016044813-A1 | PRE-SPRAY EMULSIONS AND POWDERS CONTAINING NON-POLAR COMPOUNDS | VIRUN, INC. (US) | 2016-03-24 | — | — | WO | claimed |
| EP-2811847-A1 | BEVERAGE COMPOSITIONS CONTAINING NON-POLAR COMPOUNDS | VIRUN, INC. (US) | 2014-12-17 | — | — | EP | claimed |
| US-8741373-B2 | Compositions containing non-polar compounds | VIRUN, INC. (US) | 2014-06-03 | — | — | US | claimed |
| WO-2013120025-A1 | BEVERAGE COMPOSITIONS CONTAINING NON-POLAR COMPOUNDS | VIRUN, INC. (US) | 2013-08-15 | — | — | WO | claimed |
| EP-2563164-A1 | NANOEMULSION INCLUDING SUCROSE FATTY ACID ESTER | VIRUN, INC. (US) | 2013-03-06 | — | — | EP | claimed |
| US-20120016026-A1 | Compositions containing non-polar compounds | VIRUN, INC. | 2012-01-19 | — | — | US | claimed |
| WO-2011162802-A1 | COMPOSITIONS CONTAINING NON-POLAR COMPOUNDS | VIRUN, INC. (US) | 2011-12-29 | — | — | WO | claimed |
| WO-2011119228-A1 | NANOEMULSION INCLUDING SUCROSE FATTY ACID ESTER | VIRUN, INC. (US) | 2011-09-29 | — | — | WO | claimed |
| US-20110236364-A1 | Compositions containing non-polar compounds | VIRUN, INC. | 2011-09-29 | — | — | US | claimed |
| US-20220338502-A1 | EDIBLE SILK AND METHODS OF MAKING AND USING THEREOF | EVOLVED BY NATURE, INC. | 2022-10-27 | — | — | US | disclosed |
| EP-4017537-A1 | SILK PERSONAL CARE COMPOSITIONS | Evolved by Nature, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-114466639-A | Liquid crystal composition | 花王株式会社 | 2022-05-10 | — | — | CN | disclosed |
| WO-2011162802-A1 | COMPOSITIONS CONTAINING NON-POLAR COMPOUNDS | VIRUN, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20110236364-A1 | Compositions containing non-polar compounds | VIRUN, INC. | 2011-09-29 | — | — | US | disclosed |
| WO-2011119228-A1 | NANOEMULSION INCLUDING SUCROSE FATTY ACID ESTER | VIRUN, INC. (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110236364-A1 | Compositions containing non-polar compounds | ELOVL6, ELOVL3, ELOVL5 | TLR4 3664/4885LY96 4049/4885PRKCA 1866/4885 |
| US-20160193146-A1 | COMPOSITIONS CONTAINING NON-POLAR COMPOUNDS | ELOVL6, ELOVL3, ELOVL5 | TLR4 3664/4885LY96 4049/4885PRKCA 1866/4885 |
| US-20120016026-A1 | Compositions containing non-polar compounds | ELOVL6, ELOVL3, ELOVL5 | TLR4 2879/4885LY96 3115/4885PRKCA 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.